MOLOGEN supplies Emirates with Tumor Therapy

NMC Group to treat tumor patients with cell-based gene therapy

MOLOGEN AG (ISIN DE 0006637200) has signed an agreement for use of its cell-based gene therapy with NMC Group, the leading healthcare and pharmaceutical company in the Middle East. NMC will treat tumor patients in all their hospitals in the United Arab Emirates with MOLOGEN’s cell-based gene therapy. The cell-based therapeutics will be supplied by MOLOGEN. The agreement marks the first success for MOLOGEN’s recent strategic refocus in marketing of its cell-based gene therapy in the Middle East.

According to the contract, MOLOGEN will receive a direct and significant share of the supply and profits yielded by the treatment. As the treatment license from the government health authority is expected to be granted immediately, the company anticipates positive results this year itself.

About the NMC Group:

NMC ( www.nmc.ae) is a local conglomerate, a household name, owning and managing a plethora of businesses across the region. As a leader in private healthcare, NMC owns the best hospitals with technologically advanced Diagnostic and Imaging facilities. Doctors with US and European accreditations serve the patients with zeal and fervor.

Representing many a multinational pharmaceutical companies through its excellent distribution network and retails pharmacies, NMC set up a state of the art pharmaceutical manufacturing facility in Abu Dhabi which supplies medicines to all Health Ministries in GCC countries and even some European Nations.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview